What to do: Do not consume recalled products to which you are allergic or sensitive. Do not consume the recalled product if you have celiac disease or other gluten-related disorders.
Audience: General public
Recall class: Class 1
Affected products
Brand
Product
Size
UPC
Codes
Cappola
Genoa Salami
175 g
0 63100 15111 9
Best Before 23JA03, 23JA04, and 23JA09
Issue
The affected product is being recalled from the marketplace because it contains milk and wheat which are not declared on the label.
The recalled product has been sold nationally.
What you should do
Check to see if you have recalled products
Do not consume recalled products to which you are allergic or sensitive as they may cause a serious or life-threatening reaction
If you have celiac disease or other gluten-related disorders, do not consume the recalled product as it may cause a serious or life-threatening reaction
Do not serve, use, sell or distribute recalled products
Recalled products should be thrown out or returned to the location where they were purchased
Precision BioSciences, Inc. , an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today...
XORTX Therapeutics Inc. ("XORTX" or the "Company") , a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that further to its press releases of March 11 and April 30,...
With thousands of press releases published each week, it can be difficult to keep up with everything on Cision. To help journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories...
NADclinic Group and Bontac Bio-Engineering (Shenzhen) Co., Ltd have officially entered into a dynamic strategic partnership to collaboratively focus on the future of global health and wellness. Synergistically leveraging their collective expertise...
Drug Farm announced today the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of DF-003, a first-in-class, oral, potent, highly selective alpha-kinase 1 (ALPK1) inhibitor for clinical evaluation in...
'Companion Diagnostics: Technologies and Markets' is all about using special tests alongside certain medicines to figure out which treatment will work best for each person. These tests are called companion diagnostics because they go together with...